Search Results
You are looking at 1 - 1 of 1 items for
- Author: Salvador Martín-Algarra x
- Refine by access: All content x
Search for other papers by Marta García-Goñi in
Google Scholar
PubMed
Search for other papers by Beatriz Vázquez Gutiérrez in
Google Scholar
PubMed
Search for other papers by Miguel F Sanmamed in
Google Scholar
PubMed
IdiSNA (Instituto de investigación en la Salud de Navarra), Pamplona, Spain
Search for other papers by Salvador Martín-Algarra in
Google Scholar
PubMed
IdiSNA (Instituto de investigación en la Salud de Navarra), Pamplona, Spain
Search for other papers by José Luis Pérez-Gracia in
Google Scholar
PubMed
Search for other papers by María Olmedo in
Google Scholar
PubMed
Search for other papers by Estefanía Chumbiauca in
Google Scholar
PubMed
Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain
CIBER de Fisiopatología de la Obesidad y la Nutrición, Pamplona, Spain
Search for other papers by Nerea Martín-Calvo in
Google Scholar
PubMed
Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain
Search for other papers by Juan C Galofré in
Google Scholar
PubMed
A common immune-related adverse event (irAE) with immune checkpoint inhibitors (ICIs) is thyroid dysfunction (TD-irAEs). The clinical presentation can be varied, and its association with prognosis remains unclear. We investigated the characteristics of TD-irAEs and their association with clinical outcomes among cancer patients treated with ICIs in a real-life setting. Response to treatment was assessed using RECIST v1.1. We calculated the probability of recurrence and survival associated with TD-irAEs using multivariable-adjusted regression and Cox proportional hazards models. In this single-center retrospective analysis, we included 238 patients (72% male) with a median age of 69.5 years. Primary tumors were melanoma (23.1%), lung (60.5%), or urothelial cancer (16.4%), treated with atezolizumab (23.1%), pembrolizumab (44.5%), ipilimumab (0.4%), and/or nivolumab (25.6%). Seventy (29%) patients developed TD-irAEs in a median time of 69 days (41–181). The incidence of TD-irAEs with combination therapy was higher than with monotherapy (67% vs 6.3%, P = 0.011). TD-irAE patients showed a higher objective response rate (ORR) than those without TD-irAEs (60% vs 42.3%, P = 0.013) and longer overall survival (OS) 45 vs 16 months, P < 0.006. Patients who developed TD-irAEs had a relative reduction of 77% (OR 0.23, 95% CI 0.11–0.47) in the risk of progression and of 47% in the risk of mortality (HR 0.53, 95% CI 0.36–0.80), independent of age, sex, primary tumor, or ICI regimen. TD-irAEs occur in nearly 30% of our patients receiving ICIs. In our analysis, TD-irAEs appeared to be associated with higher ORR and longer OS and showed a reduction in the risk of progression and mortality.
